Successful treatment of acquired reactive perforating collagenosis with doxycycline [13]

Acta Dermato-Venereologica

Volumn 82, Issue 5, 2002, Pages 393-395

  Brinkmeier, Thomas ^a   Schaller, Joerg ^a   Herbst, Rudolf A ^a   Frosch, Peter J ^a  

^a KLINIKUM DORTMUND   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DOXYCYCLINE; EMOLLIENT AGENT; IMMUNOGLOBULIN; LEVOCETIRIZINE; STEROID; TETRACYCLINE;

AGED; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COLLAGEN DISEASE; ECZEMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; LETTER; PAPULE; PRIORITY JOURNAL; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COLLAGEN DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEG DERMATOSES; SEVERITY OF ILLNESS INDEX; SKIN ULCER; TREATMENT OUTCOME;

EID: 0036402084     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155502320624249     Document Type: Letter

References (11)

1. Mehregan AH, Schwartz OD, Livingood CS. Reactive perforating collagenosis. Arch Dermatol 1967; 96: 277-282.
2. Faver IR, Daoud MS, Su WP. Acquired reactive perforating collagenosis. J Am Acad Dermatol 1994; 30: 575-580.
3. Theile-Oche S, Schneider LA, Reinhold K, Hunzelmann N, Krieg T, Scharffetter-Kochanek K. Acquired perforating collagenosis: Is it due to damage by scratching? Br J Dermatol 2001; 145: 173-174.
4. Yanagihara M, Fujita T, Shirasaki A, Ishiguro K, Kawahara K, Ueda K. The pathogenesis of the transepithelial elimination of the collagen bundles in acquired reactive perforating collagenosis. J Cutan Pathol 1996; 23: 398-403.
5. Zelger B, Hintner H, Aubock J, Fritsch PO. Acquired perforating dermatosis. Transepidermal elimination of DNA material and possible role of leukocytes in pathogenesis. Arch Dermatol 1991; 127: 695-700.
6. Kawakami T, Saito R. Acquired reactive perforating collagenosis associated with diabetes mellitus: Eight cases that meet Favers criteria. Br J Dermatol 1999; 140: 521-524.
7. Briggaman RA, Schechter NM, Fraki J, Lazarus GS. Degradation of the epidermal-dermal junction by proteolytic enzymes from human skin and human polymorphonuclear leukocytes. J Exp Med 1984; 160: 1027-1042.
8. Yamanaka M, Ishikawa O. Hypoxic conditions decrease the mRNA expression of proalpha1 (I) and (III) collagens and increase matrix metalloproteinases-1 of dermal fibroblasts in three-dimensional cultures. J Dermatol Sci 2000; 24: 99-104.
9. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: Inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 2001; 8: 305-316.
10. Farrell AM. Acquired perforating dermatosis in renal and diabetic patients. Lancet 1997; 349: 895-896.
11. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2: 297-321.